The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct

[1]  R. Kimmig,et al.  MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.

[2]  P. Kufer,et al.  Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. , 2006, Molecular immunology.

[3]  P. Kufer,et al.  T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2006, Cancer Immunology, Immunotherapy.

[4]  R. Kimmig,et al.  Immunotherapy of malignant ascites with trifunctional antibodies , 2005, International journal of cancer.

[5]  B. Wollenberg,et al.  Prednisolone reduces TNF-alpha release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. , 2005, Anticancer research.

[6]  P. Kufer,et al.  BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.

[7]  G. Ledderose,et al.  Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. , 2005, Anticancer research.

[8]  P. Hoffmann,et al.  Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct , 2005, International journal of cancer.

[9]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Tuckermann,et al.  MOLECULAR MECHANISMS OF GLUCOCORTICOIDS IN THE CONTROL OF INFLAMMATION AND LYMPHOCYTE APOPTOSIS , 2005, Critical reviews in clinical laboratory sciences.

[11]  A. Duits,et al.  CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphoma , 1995, Cancer Immunology, Immunotherapy.

[12]  S. Abrams.  Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response. , 2005, Frontiers in bioscience : a journal and virtual library.

[13]  T. Gajewski.  Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1. , 2004, Current opinion in investigational drugs.

[14]  M. Vitale,et al.  Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. , 2004, International journal of oncology.

[15]  S. Paul,et al.  Gene-based vaccines and immunotherapeutics , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Bubeník,et al.  MHC class I down-regulation: tumour escape from immune surveillance? (review). , 2004, International journal of oncology.

[17]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[18]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[19]  B. Dörken,et al.  Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2003, Leukemia.

[20]  G. Bastert,et al.  Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma , 2002, International journal of cancer.

[21]  P. Hoffmann,et al.  Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody , 2002, International journal of cancer.

[22]  P. Henkart,et al.  Surface Cathepsin B Protects Cytotoxic Lymphocytes from Self-destruction after Degranulation , 2002, The Journal of experimental medicine.

[23]  Gerhard Moldenhauer,et al.  Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma1 , 2002, The Journal of Immunology.

[24]  Richard A. Flavell,et al.  Mechanism of Transforming Growth Factor β–induced Inhibition of T Helper Type 1 Differentiation , 2002, The Journal of experimental medicine.

[25]  Takuma Hayashi,et al.  Development of spontaneous uterine tumors in low molecular mass polypeptide-2 knockout mice. , 2002, Cancer research.

[26]  U. Ritz,et al.  Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. , 2001, International journal of oncology.

[27]  G. Griffiths,et al.  The immunological synapse of CTL contains a secretory domain and membrane bridges. , 2001, Immunity.

[28]  R. Offringa,et al.  Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Withoff,et al.  Bi-specific antibody therapy for the treatment of cancer. , 2001, Current opinion in molecular therapeutics.

[30]  T. Grogan,et al.  Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  B. Seliger,et al.  Antigen-processing machinery breakdown and tumor growth. , 2000, Immunology today.

[32]  M. Little,et al.  Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells1 , 2000, The Journal of Immunology.

[33]  B. Dörken,et al.  A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. , 2000, Blood.

[34]  Cynthia S. Johnson,et al.  Loss of B 7 . 2 ( CD 86 ) and Intracellular Adhesion Molecule 1 ( CD 54 ) Expression Is Associated with Decreased Tumor-infiltrating T Lymphocytes in Diffuse B-cell Large-cell Lymphoma 1 , 2000 .

[35]  Bert,et al.  The Efficacy of CD 3 x CD 19 Bispecific Monoclonal Antibody ( BsAb ) in a Clonogenic Assay : The Effect of Repeated Addition of BsAb and Interleukin-2 , 2000 .

[36]  V. Diehl,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[37]  V. Diehl,et al.  Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. , 1999, Cancer research.

[38]  S Ferrone,et al.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.

[39]  E. Venetsanakos,et al.  High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. , 1997, British Journal of Cancer.

[40]  W. de Lau,et al.  The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. , 1995, Blood.

[41]  K. Frei,et al.  Expression of TGF-beta 2 in human glioblastoma: a role in resistance to immune rejection? , 1991, Ciba Foundation symposium.